이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

CAR-T 이전의 재발성 및 불응성 거대 B세포 림프종에 대한 Odronextamab

2026년 11월 17일 업데이트: University of Washington

최종 림프종 지향 치료법 전 재발성/불응성 거대 B세포 림프종에 대한 오드로넥스타맙

This phase II trial tests the effectiveness of odronextamab given before chimeric antigen receptor T (CAR-T) cell therapy (bridging therapy) in patients with large B-cell lymphomas that have come back after a period of improvement (relapsed) or that have not responded to previous treatment (refractory). Odronextamab is a bispecific antibody that can bind to two different antigens at the same time. Odronextamab binds to CD3, a T-cell surface antigen, and CD20 (a tumor-associated antigen that is expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell cancers) and may interfere with the ability of cancer cells to grow and spread. Bridging therapy has been used to maintain disease control and to increase the chance of successful receipt of CAR-T cell therapy. However, bridging therapy is typically given after leukapheresis, which does not help prevent disease progression between the decision for CAR-T cell therapy and leukapheresis. Giving odronextamab as bridging therapy before leukapheresis may delay disease progression to allow leukapheresis and increase the likelihood of successful CAR-T cell therapy in patients with relapsed or refractory large B-cell lymphomas.

연구 개요

상태

모병

개입 / 치료

상세 설명

OUTLINE:

Patients receive odronextamab intravenously (IV) on days 1, 2, 8, 9, 15 and 16 of cycle 1 (dose step-up), and on days 1, 8 and 15 of cycles 2-4 and then once every other week of remaining cycles. Cycles repeat every 21 days for the first 4 cycles, then every other week for up to a total of 12 months (including the first 2 cycles). After 2 cycles, patients undergo leukapheresis followed by lymphodepletion and CAR-T infusion per standard of care. If there is a significant delay of leukapheresis, patients may receive up to 12 additional weeks of treatment. Patients who achieve CR after cycle 2 may opt out of leukapheresis and CAR-T cell infusion and may continue to receive odronextamab in the absence of disease progression or unacceptable toxicity. Patients undergo positron emission tomography (PET)/computed tomography (CT), collection of blood and oral or rectal swab samples and tissue biopsy throughout the study. Additionally, patients may undergo lumbar puncture and bone marrow aspiration and/or biopsy on study.

After completion of study treatment, patients are followed till 90 days or the initiation of the next lymphoma directed therapy for toxicity check, and total duration of follow-up is up to 5 years.

연구 유형

중재적

등록 (추정된)

27

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Washington
      • Seattle, Washington, 미국, 98109
        • 모병
        • Fred Hutch/University of Washington Cancer Consortium
        • 수석 연구원:
          • Mengyang Di, MD, PhD
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Histologically confirmed large B cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, DLBCL arising from indolent lymphoma, follicular lymphoma (FL) grade 3B
  • Measurable disease, defined as at least one measurable lesion ≥ 15 mm on PET, CT, or magnetic resonance imaging (MRI) within one month of screening, according to the International Working Group consensus response evaluation criteria in lymphoma
  • Prior frontline therapy for large B cell lymphoma must have failed the patient, and criteria must be met for receiving commercial axicabtagene ciloleucel (axi-cel), lisocabtagene maraleucel (liso-cel), or tisagenlecleucel (tisa-cel) per Food and Drug Administration (FDA) label
  • Age ≥ 18 years
  • Capable of understanding and providing a written informed consent
  • Prior treatment with an anti-CD20 antibody therapy
  • Eastern Cooperative Oncology Group performance status of 0-1; we allow enrollment of patients with a performance status of 2 if it is attributed to lymphoma per discretion of the treating physician or principal investigator (PI)
  • Creatinine clearance ≥ 45 mL/min calculated by Cockcroft-Gault equation
  • Total bilirubin ≤ 1.5 x the upper limit of normal (ULN), except in patients with Gilbert's syndrome
  • Aspartate aminotransferase and alanine aminotransferase ≤ 2.5 x the ULN
  • Adequate pulmonary function, defined as ≤ grade 1 dyspnea and oxygen saturation (SpO2) ≥ 92% on room air
  • Adequate cardiac function, defined as left ventricular ejection fraction ≥ 50% and without evidence for pericardial effusion
  • Platelet count ≥ 75 x 10^9 /L
  • Hemoglobin (Hg) level ≥ 9 g/dL
  • Absolute neutrophil count (ANC) ≥ 1 x 10^9 /L
  • Patients with bone marrow involvement or splenic sequestration: Platelet count ≥ 25 x 10^9 /L
  • Patients with bone marrow involvement or splenic sequestration: Hg ≥ 7.0 g/dL
  • Patients with bone marrow involvement or splenic sequestration: ANC ≥ 0.5 x 10^9 /L
  • Negative serum pregnancy test within 2 days of initiating odronextamab for women of childbearing potential (WOCBP), defined as those who have not been surgically sterilized or who have not been free of menses for at least 1 year
  • Fertile male and WOCBP patients must be willing to use highly effective contraceptive methods from study recruitment to at least 6 months after the CAR T-cell infusion
  • Patients must not provide egg or sperm donation until at least 6 months after the completion of the last dose of Odron

Exclusion Criteria:

  • Detectable cerebrospinal fluid malignant cells, or brain metastases, or with a history of cerebrospinal fluid malignant cells or brain metastases. Patients with a history of secondary central nervous system (CNS) lymphoma may be eligible provided that there has been no evidence of CNS disease from lymphoma for at least 3 months at the time of screening
  • History of a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with central nervous system (CNS) involvement
  • Standard anti-neoplastic chemotherapy (non-biologic) within 5-times the half-life or within 2 weeks, whichever is shorter, prior to first administration of study drug
  • Standard radiotherapy within 2 weeks of first administration of study drug
  • Prior treatment with an anti-CD20 x anti-CD3 bispecific therapy, unless all the following are met: disease responded to prior bispecific therapy (CR or PR per Lugano criteria) and did not experience disease progression within 12 months of the last dose of prior bispecific therapy, and the tumor must still express CD20 (CD20 examination per standard of care [SOC])
  • Allogeneic stem cell transplantation
  • Any CAR-T cell therapy
  • Patients may not be receiving other investigational agents
  • Treatment with rituximab, alemtuzumab, or other investigational or commercial biologic agent within 2 weeks prior to first administration of study drug
  • Immunosuppressive therapy (other than biologic) within 2 weeks of first administration of study drug
  • Treatment with an investigational non-biologic agent within 2 weeks of first administration of study drug
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition of study drug
  • History of hypersensitivity to any compound in the tetracycline antibiotics group
  • Concurrent active malignancy for which the patient is receiving systemic treatment, unless approved by PI
  • Known active and uncontrolled bacterial, viral, fungal, mycobacterial, or other infection
  • Evidence of significant concurrent disease or medical condition that could interfere with the conduct of the study, or put the patient at significant risk including, but not limited to, significant cardiovascular disease (e.g., New York Heart Association class III or IV cardiac disease, myocardial infarction within the previous 6 months, unstable arrhythmias, or unstable angina) and/or significant pulmonary disease (e.g., obstructive pulmonary disease and history of symptomatic bronchospasm)
  • Ongoing systemic corticosteroid treatment, with the exception of corticosteroid use for other (non-tumor and non-immunosuppressive) indications up to a maximum of 10 mg/day of prednisone or equivalent. A short course of corticosteroid for lymphoma disease control during screening is allowed
  • Infection with human immunodeficiency virus (unless viral load is undetectable and CD4 count ≥ 400) or chronic infection with hepatitis B virus or hepatitis C virus. Patients with hepatitis B (hepatitis B surface antigen positive [HepBsAg+]) with controlled infection were permitted upon consultation with the physician managing the infection
  • Known hypersensitivity to both allopurinol and rasburicase
  • Pregnant or breast-feeding women
  • Administration of live vaccination within 28 days of first administration of study drug

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Treatment (odronextamab)

Patients receive odronextamab IV based on the following schedules:

  • Step-up dosing during cycle 1: 0.2 mg on C1D1, 0.5 mg on C1D2, 2 mg on C1D8 and C1D9, respectively, and 10 mg on C1D15 and C1D16, respectively (0.7/4/20 regimen).
  • Dosing during cycles 2-4: Odron will be given at 160 mg weekly.
  • Once every other week at 320 mg of remaining cycles.

Please see the Detailed Description for additional information.

Undergo bone marrow biopsy

다른 이름들:
  • 골수 생검
  • 생검, 골수

Ancillary studies

Undergo bone marrow aspiration

Undergo lumbar puncture

다른 이름들:
  • LP
  • 척추 천자

Undergo PET/CT

다른 이름들:
  • 의료 영상, 양전자 방출 단층 촬영
  • 애완 동물
  • PET 스캔
  • 양전자 방출 단층 촬영 스캔
  • 양전자 방출 단층 촬영
  • 양성자 자기 공명 분광 이미징
  • PT
  • 양전자방출단층촬영(시술)

Undergo PET/CT

다른 이름들:
  • CT
  • 고양이
  • 고양이 스캔
  • 컴퓨터 축 단층 촬영
  • 전산화 단층 촬영
  • CT 스캔
  • 단층 촬영
  • 컴퓨터 축 단층 촬영(시술)
  • 컴퓨터 단층촬영(CT) 스캔

Undergo tissue biopsy

다른 이름들:
  • 비엑스

Undergo leukapheresis

다른 이름들:
  • 백혈구 분리술
  • 치료 백혈구성분채집술
  • 백혈구 흡착 성분채집술
  • 백혈구 감소 성분채집술

Given IV

다른 이름들:
  • REGN1979
  • 항-CD20 x 항-CD3 이중특이적 단일클론 항체 REGN1979
  • 누구 11035

Undergo collection of blood and oral or rectal swab samples

다른 이름들:
  • 생물학적 샘플 수집
  • 생체 표본 수집
  • 표본 수집

Undergo CAR-T cell therapy

다른 이름들:
  • CAR T 주입
  • CAR T 테라피
  • CAR T 세포 치료
  • 키메라 항원 수용체 T 세포 주입

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Failure to undergo leukapheresis
기간: Up to 5 years

Will include failures due to disease progression or adverse events (AEs) due to odronextamab (Odron), or requirement of other lymphoma-directed therapy for bridging before leukapheresis due to lack of response. Will report the total number and percentage with 95% confidence interval (CI).

Up to 5 years

2차 결과 측정

결과 측정
측정값 설명
기간
Receipt of chimeric antigen receptor T-cell therapy (CAR-T)
기간: Up to 5 years

Will estimate the total number and percentage with 95% CI of patients who receive CAR-T cell infusion. Patients who achieve complete response (CR) after 2 cycles of Odron and opt out of leukapheresis will be excluded from the estimation of the percentage. Will also report the reasons why patients do not eventually receive CAR-T.

Up to 5 years
Overall response rate (ORR) following bridging prior to CAR-T infusion
기간: Up to 5 years

ORR includes CR, partial response, stable disease. Will report the total number and percentage with 95% CI of patients who achieve response on positron emission tomography/computed tomography (PET/CT) scans before CAR-T cell infusion. Patients who receive CAR-T cell infusion will be included in the estimation of this percentage.

Up to 5 years
Progression free survival (PFS) following CAR-T infusion
기간: Up to 2 years

Will estimate the median with interquartile range of the progression free duration. Will also report the percentage with 95% CI.

Up to 2 years
CR rate
기간: At 1 month after CAR-T

Will report the total number and percentage with 95% CI of patients who achieve CR on the PET/CT scans following CAR-T cell infusion.

At 1 month after CAR-T
PFS in patients who achieve CR after 2 cycles of Odron, choose to opt out of CAR-T, and receive up to a total of 12 months of Odron
기간: Up to 5 years

Will report the median duration of PFS with 95% CI in this group of patients.

Up to 5 years
Incidence of AEs
기간: Up to 90 days after the last dose of Odron or the initiation of the next lymphoma directed therapy, whichever occurs first

All AEs will be graded in severity according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. Cytokine release syndrome and immune effector cell associated neurotoxicity syndrome will be graded by the American Society for Transplantation and Cellular Therapy Consensus Grading systems. Will report the rate and grade of each AE, including unsuccessful CAR-T production.

Up to 90 days after the last dose of Odron or the initiation of the next lymphoma directed therapy, whichever occurs first

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 수석 연구원: Mengyang Di, MD, PhD, Fred Hutch/University of Washington Cancer Consortium

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 9월 4일

기본 완료 (추정된)

2028년 4월 10일

연구 완료 (추정된)

2033년 4월 11일

연구 등록 날짜

최초 제출

2025년 1월 14일

QC 기준을 충족하는 최초 제출

2025년 1월 14일

처음 게시됨 (실제)

2025년 1월 20일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 18일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 17일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • RG1124641
  • NCI-2024-10534 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
  • FHIRB0020747 (기타 식별자: Fred Hutch/University of Washington Cancer Consortium)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .